Abstract
HWA 486 was investigated for its ability to modify the development of adjuvant-induced polyarthritis in Lewis rats. HWA 486 (20 mg/kg/day p.o.), dosed for 8 or 16 days beginning with the day of adjuvant administration, significantly reduced edema, fibrinogen levels, and erythrocyte sedimentation rates (ESR) 42 days later. When HWA 486 (20 mg/kg/day, p.o.) and cyclosporin A (CsA 15 mg/kg/day, p.o.) were tested in the 8-day treatment regimen, the antiarthritic effects of HWA 486 were more sustained. Both compounds reduced the delayed hypersensitivity (DTH) response on day 9 followed by a rebound to an enhanced DTH response on day 21. The PHA-induced mitogenic response of splenocytes from arthritic rats was suppressed on day 9. Treatment with HWA 486 but not CsA restored the splenocyte response to the level of the negative controls.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
R. R. Bartlett and R. Schleyerbach,Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmac.7, 7–18 (1985).
R. R. Bartlett,Immunopharmacological profile of HWA 486, a novel isoxazol derivative — II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone or cyclosporin A. Int. J. Immunopharmac.8, 199–204 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pasternak, R.D., Wadopian, N.S., Wright, R.N. et al. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents and Actions 21, 241–243 (1987). https://doi.org/10.1007/BF01966478
Issue Date:
DOI: https://doi.org/10.1007/BF01966478